1983
DOI: 10.1016/s0033-3182(83)73188-9
|View full text |Cite
|
Sign up to set email alerts
|

Anticoagulant for dementia?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

1989
1989
1997
1997

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 2 publications
0
2
0
Order By: Relevance
“…No systematic study has been carried out to evaluate whether or not the vascular changes are accompanied by hemostatic disturbances in patients with dementia, particularly in those with Alzheimer's disease. Despite this lack of information about the behaviour of hemostasis, the use of anticoagulant therapy has been proposed for the treatment of patients with Alzheimer's dementia (3).…”
Section: Introductionmentioning
confidence: 99%
“…No systematic study has been carried out to evaluate whether or not the vascular changes are accompanied by hemostatic disturbances in patients with dementia, particularly in those with Alzheimer's disease. Despite this lack of information about the behaviour of hemostasis, the use of anticoagulant therapy has been proposed for the treatment of patients with Alzheimer's dementia (3).…”
Section: Introductionmentioning
confidence: 99%
“…No controlledtrials dealingwith treatment of VaD by meansof drugsthat rdTect hemostasisare available.A pilot study (8) with aspirin(325 mg dailyfor 3 years) gave promisingresults. The xantinederivativepentoxifillinehas also been successfullyused for treatmentof elderlypatientswith vasculardementia(9); in two other series (10,11) this drug showed to be able to improve the haemorheologicalpattern (by decreasing blood viscosity and improvingred blood cell deformability)parallel to a favorable trend of psychobehavioral scoresin cognitivelyimpairedold subjects.The use of anticoagulanttherapy has also been proposed in senileand preseniledementia (12). Sulodexideis a highlypurifiedpreparationcontaininga heparin fraction with a high afllnityfor antithrombinIII (80°/0)and a dermatanfractionwith affinityfor heparincofactor II (20°/0) (13).…”
mentioning
confidence: 99%